# Menopause for NEET PG OBG: Definition, Stages, Hot Flushes, Genitourinary Syndrome, Hormone Therapy Rules and Non-hormonal Options

Source: https://tracknation.in/story/menopause-for-neet-pg-obg-definition-stages-hot-flushes-genitourinary-syndrome-hormone-therapy-rules-and-non-hormonal-options (TrackNation — free UPSC notes with PYQs)

> NEET PG Gynaecology: menopause definition and ages (premature, early, normal), stages and FSH, vasomotor symptoms, genitourinary syndrome of menopause, hormone therapy (progestogen with a uterus, the under-60/10-year window, breast and VTE risks, transdermal route), non-hormonal drugs incl. fezolinetant, and bone screening, with a diagram, hooks, MCQs and cards.

## Start Here

🎯 **Exam priority: Moderate–high.** *Expect: 12-month definition, average and premature/early ages, FSH role, hot flush facts, GSM
and its local treatment, why a progestogen is added, the age/time window for starting hormone therapy, its risks, and non-hormonal
alternatives.*

CBME mapping: **OG32**.

*Menopause definitions, symptoms, hormone therapy and alternatives. Drawn by TrackNation.*

## Definitions and Stages (MSD)

- **Menopause** is diagnosed **retrospectively after 12 months without menses**; average age **51** (US), normal range
**45–55**. Smoking, high altitude and undernutrition bring it earlier.

- **Premature <40** (= primary ovarian insufficiency, treated with oestrogen-progestogen); **early 40–45**.

- **Perimenopause**: years before and 1 year after the last period — the most symptomatic phase. The menopausal transition lasts
about **4–8 years**; late transition = gaps of **≥60 days**, FSH **>25 IU/L**. **FSH is rarely needed** (e.g. after
hysterectomy or at a young age).

- Rule out pregnancy, other causes of amenorrhoea and **uterine cancer** in abnormal bleeding.

## Symptoms (MSD)

- **Hot flushes/night sweats** in **75–85%**, usually **starting before periods stop**, lasting on average **7.4 years**
(sometimes >10).

- **Genitourinary syndrome of menopause (GSM)**: falling oestrogen → **dryness, burning, dyspareunia**, urgency, dysuria, recurrent
UTIs. It is **chronic**; treatment must continue.

- Others: sleep disturbance, mood change; long-term **bone loss** — screen bone density in women at high fracture risk.

## Treatment (MSD)

- **Hormone therapy (HT)** is the **most effective** treatment for symptoms. With a **uterus, oestrogen must be combined with a
progestogen** (prevents endometrial neoplasia) — except **very low-dose vaginal oestrogen**; conjugated oestrogens + bazedoxifene need no
progestogen.

- **Timing**: benefits most likely exceed harms in healthy women **<60 years or <10 years after menopause**; starting
**>60 or >10–20 years after** is generally not recommended (more coronary disease).

- Risks: **breast cancer rises after 3–5 years of combined therapy** (oestrogen alone: slightly lower at 7 years in WHI);
**VTE and stroke** lower with **low-dose transdermal** oestrogen. HT reduces bone loss and fractures.

- **Non-hormonal** (all less effective than HT): **fezolinetant** (neurokinin-3 antagonist; check LFTs), elinzanetant (NK1/NK3),
**SSRIs/SNRIs**, gabapentin, oxybutynin. Raloxifene for bone protection in women at high breast-cancer risk.

- **GSM**: lubricants and moisturisers; first-line drugs — **low-dose vaginal oestrogen**, **vaginal DHEA (prasterone)** or
**ospemifene** (oral SERM; VTE risk).

## Traps the Examiner Sets

- Menopause is a clinical, retrospective diagnosis — not an FSH diagnosis.

- Oestrogen alone is only for women without a uterus (vaginal low dose excepted).

- Starting HT after 60 or long after menopause is not advised.

- Premature menopause is before 40; early is 40–45.

## Memory Hooks & Shortcuts

*Shortcuts to lock in this article's numbers and lists. Each one only re-packages facts proven above.*

- 🧠 **'12 months, 51 years, 40 premature, 45 early'** — definitions

- 🧠 **'Uterus = add Progestogen' (vaginal low-dose oestrogen excepted)** — HT

- 🧠 **HT window '60 or 10': under 60 or within 10 years** — timing

- 🧠 **'Patch protects' — transdermal oestrogen means less clotting and stroke** — route

- 🧠 **Fezolinetant: 'NK3 blocks the hot flush, check the liver'** — non-hormonal

## Rapid-Revision Cards

- 12 months no menses.

- 51 (normal 45–55).

- <40.

- 40–45.

- Smoking, altitude, undernutrition.

- Rarely needed.

- ≥60-day gaps; FSH >25.

- 75–85%; ~7.4 y.

- Dryness, dyspareunia, urgency.

- Hormone therapy.

- Add progestogen.

- Low-dose vaginal oestrogen.

- No progestogen needed.

- <60 or <10 y.

- >60 or >10–20 y.

- After 3–5 y combined.

- Transdermal (VTE, stroke).

- NK3 antagonist; LFTs.

- Vaginal E, DHEA, ospemifene.

- Raloxifene.

- E + P therapy.

## Sources

*Facts in this article were checked against these documents.*

- MSD Manual Professional: Menopause; Genitourinary Syndrome of Menopause; Primary Ovarian Insufficiency — Merck & Co. (MSD Manuals), 2025–26 (link)

- Competency Based Undergraduate Curriculum, Vol III: Obstetrics & Gynaecology (OG32) — National Medical Commission, 2024

## Test Yourself: Practice Questions

Thirty questions in NEET PG style, most of them clinical vignettes.

## Practice Questions (NEET PG pattern)

*Original questions written in the style of the exam: +4 for a correct answer, −1 for a wrong one. Every answer
was checked against the sources listed above. NEET PG papers are not published by NBEMS, so these are not past-paper questions.*

**Q1.** Menopause is diagnosed when there has been no menstruation for

- (a) 6 months

- (b) 12 months

- (c) 3 months

- (d) 24 months

**Answer: (b)** — Retrospective.

**Q2.** The average age of natural menopause (MSD, US data) is

- (a) 40 years

- (b) 51 years

- (c) 55 years

- (d) 45 years

**Answer: (b)** — Normal 45–55.

**Q3.** A factor that makes menopause occur earlier is

- (a) oral contraceptive use

- (b) multiparity

- (c) smoking

- (d) obesity

**Answer: (c)** — Also altitude, undernutrition.

**Q4.** Menopause at 38 years is termed

- (a) normal

- (b) early

- (c) premature (primary ovarian insufficiency)

- (d) late

**Answer: (c)** — <40.

**Q5.** Menopause at 43 years is termed

- (a) normal

- (b) early

- (c) late

- (d) premature

**Answer: (b)** — 40–45.

**Q6.** A 50-year-old with 12 months of amenorrhoea and hot flushes asks for an FSH test. MSD says FSH is

- (a) needed monthly

- (b) rarely necessary — diagnosis is clinical

- (c) mandatory

- (d) the only way to diagnose

**Answer: (b)** — Except after hysterectomy/young.

**Q7.** Hot flushes affect about

- (a) 75–85% of women

- (b) 100%

- (c) 5%

- (d) 25%

**Answer: (a)** — Average 7.4 years.

**Q8.** Vasomotor symptoms last on average

- (a) 6 months

- (b) 7.4 years

- (c) 1 month

- (d) 20 years always

**Answer: (b)** — Can exceed 10 years.

**Q9.** Hot flushes usually begin

- (a) only 5 years after menopause

- (b) before periods stop

- (c) never in perimenopause

- (d) only after surgery

**Answer: (b)** — MSD.

**Q10.** The late menopausal transition is marked by

- (a) regular cycles

- (b) amenorrhoea of ≥60 days and FSH >25 IU/L

- (c) low FSH

- (d) heavy regular periods

**Answer: (b)** — STRAW-type staging.

**Q11.** The most effective treatment for menopausal vasomotor symptoms is

- (a) SSRIs

- (b) black cohosh

- (c) hormone therapy

- (d) gabapentin

**Answer: (c)** — MSD.

**Q12.** A 52-year-old with an intact uterus starts systemic oestrogen. She must also take

- (a) a progestogen

- (b) testosterone

- (c) nothing else

- (d) thyroxine

**Answer: (a)** — Prevents endometrial neoplasia.

**Q13.** Which oestrogen can be used without a progestogen in a woman with a uterus?

- (a) oral conjugated oestrogen 0.625 mg alone

- (b) transdermal oestradiol patch alone

- (c) very low-dose vaginal oestrogen for GSM

- (d) any oestrogen

**Answer: (c)** — Also CE + bazedoxifene.

**Q14.** Conjugated oestrogens can be given without a progestogen when combined with

- (a) tamoxifen

- (b) bazedoxifene

- (c) clomiphene

- (d) letrozole

**Answer: (b)** — A SERM.

**Q15.** Benefits of HT most likely outweigh harms in healthy symptomatic women who are

- (a) over 70

- (b) any age equally

- (c) 20 years past menopause

- (d) under 60 or within 10 years of menopause

**Answer: (d)** — Timing window.

**Q16.** A 68-year-old, 18 years post-menopause, asks to start HT for prevention. MSD advice:

- (a) generally not recommended

- (b) mandatory for bone

- (c) start high-dose oestrogen

- (d) start oral HT at once

**Answer: (a)** — More coronary risk.

**Q17.** Breast cancer risk with standard combined HT begins to rise after about

- (a) 1 month

- (b) 20 years

- (c) it never rises

- (d) 3–5 years

**Answer: (d)** — MSD.

**Q18.** VTE and stroke risk with HT may be lower with

- (a) injectable oestrogen

- (b) oral oestrogen with tamoxifen

- (c) high-dose oral oestrogen

- (d) low-dose transdermal oestrogen

**Answer: (d)** — MSD.

**Q19.** In WHI, oestrogen-alone therapy in women without a uterus

- (a) doubled breast cancer

- (b) had no data

- (c) caused endometrial cancer

- (d) slightly lowered breast cancer risk at 7 years

**Answer: (d)** — Benefit faded later.

**Q20.** HT in postmenopausal women

- (a) increases fractures

- (b) causes osteomalacia

- (c) reduces bone loss and fractures

- (d) has no bone effect

**Answer: (c)** — MSD.

**Q21.** Fezolinetant treats hot flushes by

- (a) blocking dopamine

- (b) blocking neurokinin-3 receptors

- (c) replacing oestrogen

- (d) blocking serotonin reuptake

**Answer: (b)** — Check LFTs.

**Q22.** Before starting fezolinetant you must check

- (a) bone density

- (b) serum calcium

- (c) TSH

- (d) liver function tests

**Answer: (d)** — Then 3-monthly.

**Q23.** Non-hormonal drugs for hot flushes, compared with HT, are

- (a) equally effective always

- (b) more effective

- (c) contraindicated

- (d) less effective

**Answer: (d)** — MSD.

**Q24.** A breast cancer survivor wants non-hormonal relief of hot flushes. Options include

- (a) systemic oestrogen

- (b) SSRIs/SNRIs, gabapentin or a neurokinin antagonist

- (c) tibolone

- (d) testosterone

**Answer: (b)** — MSD list.

**Q25.** Vaginal dryness, dyspareunia and urinary urgency after menopause are called

- (a) Asherman syndrome

- (b) PMOS

- (c) genitourinary syndrome of menopause

- (d) vaginismus

**Answer: (c)** — Oestrogen deficiency.

**Q26.** First-line drug treatments for moderate–severe GSM include

- (a) GnRH agonists

- (b) low-dose vaginal oestrogen, vaginal DHEA or ospemifene

- (c) danazol

- (d) oral antibiotics

**Answer: (b)** — Plus lubricants.

**Q27.** GSM treatment should be

- (a) avoided

- (b) stopped after symptoms settle

- (c) given for 1 week only

- (d) continued long term (chronic condition)

**Answer: (d)** — Recurs on stopping.

**Q28.** Ospemifene is an oral SERM that carries a risk of

- (a) hyperkalaemia

- (b) lactic acidosis

- (c) hypoglycaemia

- (d) venous thrombosis

**Answer: (d)** — MSD.

**Q29.** A postmenopausal woman at high breast cancer risk needs fracture prevention. MSD mentions

- (a) systemic oestrogen alone

- (b) progestogen alone

- (c) raloxifene

- (d) tamoxifen for bone

**Answer: (c)** — SERM.

**Q30.** A 35-year-old with primary ovarian insufficiency should usually receive

- (a) no treatment

- (b) progestogen only

- (c) clomiphene

- (d) combined oestrogen-progestogen therapy

**Answer: (d)** — Until natural menopause age.

### Active Recall

From memory: define menopause and its premature and early forms, describe stages and symptoms including GSM, state hormone therapy rules, timing and risks, and list non-hormonal and local treatments.
